Phase Ib trial of aldoxorubicin plus gemcitabine in patients with relapsed ovarian cancer

Trial Profile

Phase Ib trial of aldoxorubicin plus gemcitabine in patients with relapsed ovarian cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Aldoxorubicin (Primary) ; Gemcitabine
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 18 Nov 2014 New trial record
    • 29 Sep 2014 The FDA has granted aldoxorubicin Orphan Drug Designation for ovarian cancer, and this phase Ib trial is planned, according to a CytRx Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top